PHP
STIM icon

Parkman Healthcare Partners’s Neuronetics STIM Stock Holding History

Parkman Healthcare Partners’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-85,866
Closed -$273K – 92
2022
Q3 		$273K Buy
+85,866
New +$312K 0.08% 86

Other funds holding STIM

CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
MAG
Millrace Asset Group Berwyn, Pennsylvania $98.4M AUM 63.71% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
FWC
First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return

Parkman Healthcare Partners's STIM Position: Q4 2022 in Review

Parkman Healthcare Partners sold out of Neuronetics (STIM) in Q4 2022, closing a stake of 85,866 shares — an estimated $273K sold.

Parkman Healthcare Partners first reported a position in STIM in Q3 2022 and held it in 1 quarter. The position peaked at $273K in Q3 2022. 82 funds tracked by Wall St. Rank hold STIM as of Q4 2022.

  • Parkman Healthcare Partners reported no remaining Neuronetics position as of Q4 2022 after selling out during the quarter.
  • Parkman Healthcare Partners sold 85,866 Neuronetics shares in Q4 2022, an estimated $273K.
  • Parkman Healthcare Partners first reported a position in Neuronetics in Q3 2022 and held it in 1 quarter.
  • Parkman Healthcare Partners's Neuronetics position peaked at $273K in Q3 2022.
  • 82 funds tracked by Wall St. Rank held Neuronetics as of Q4 2022.

Based on Parkman Healthcare Partners's 13F filing for Q4 2022, filed 13 Feb 2023.